AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30817455 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG
Number of subjects: 1347
Study 30817455 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Sokolow‐Lyon index, Cornell voltage duration product, and/or Romhilt‐Estes score at least 4
Number of subjects: 1347
Study 30817455 — intervention group
Group type: COMPARATOR
Intervention: CT signs of LVH
Number of subjects: 1347
Study 28802512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 10939
Study 28802512 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10939
Study 25935843 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional motor control exercise
Number of subjects: 29
Study 25935843 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated hip abductor strengthening
Number of subjects: 29
Study 24174667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing task load during the delay
Number of subjects: 0
Study 24174667 — intervention group
Group type: COMPARATOR
Intervention: Task-free delays
Number of subjects: 0
Study 24174667 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall encoding of delayed intentions
Number of subjects: 0
Study 24174667 — intervention group
Group type: EXPERIMENTAL
Intervention: Rostrolateral PFC (BA 46)
Number of subjects: 0
Study 23939305 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinesia subscale alone group (n = 56)
Number of subjects: 112
Study 23939305 — intervention group
Group type: COMPARATOR
Intervention: Full scale group (n = 56)
Number of subjects: 112
Study 23939305 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bradykinesia subscale alone and full scale)
Number of subjects: 112
Study 19917367 — intervention group
Group type: EXPERIMENTAL
Intervention: Equimolar enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 25
Study 17909129 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention (22 weekly group sessions for parents and preschoolers and 10 biweekly home visits over 6-8 months)
Number of subjects: 92
Study 17909129 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 92
Study 15049991 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of 1% testosterone gel applied once or twice daily
Number of subjects: 18
Study 15049991 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of 2% testosterone gel applied once daily
Number of subjects: 18
Study 15049991 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% testosterone gel applied once daily
Number of subjects: 18
Study 15049991 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of 2% testosterone gel applied once or twice daily
Number of subjects: 18
Study 11574416 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia (plasma glucose levels of 2.6 mmol/l) in hypoglycemia-unaware patients
Number of subjects: 13
Study 11574416 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia (plasma glucose levels of 2.6 mmol/l) in hypoglycemia-aware patients
Number of subjects: 13
Study 9663185 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg S(+)-ibuprofen
Number of subjects: 0
Study 9663185 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg S(+)-ibuprofen
Number of subjects: 0
Study 9663185 — intervention group
Group type: COMPARATOR
Intervention: 400 mg racemic ibuprofen
Number of subjects: 0
Study 9663185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7816992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg qid)
Number of subjects: 134
Study 7816992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 2660555 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g twice daily
Number of subjects: 254
Study 2660555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 4559028 — intervention group
Group type: EXPERIMENTAL
Intervention: Opipramol
Number of subjects: 14
Study 4559028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30027389 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 236
Study 28894822 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory training (OT) using essential oils at random concentrations for 6 months
Number of subjects: 35
Study 28894822 — intervention group
Group type: COMPARATOR
Intervention: Control group (no olfactory training)
Number of subjects: 35
Study 26223821 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive offered (up to $50)
Number of subjects: 1850
Study 26223821 — intervention group
Group type: COMPARATOR
Intervention: No incentive offered
Number of subjects: 1850
Study 21883718 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored educational intervention (2-day interactive workshop for higher readiness GPs and 2-day large group meeting for lower readiness GPs)
Number of subjects: 192
Study 21883718 — intervention group
Group type: COMPARATOR
Intervention: Standard educational programme on the same topic (Control)
Number of subjects: 192
Study 21786177 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant 3 mg/kg IV infusion
Number of subjects: 0
Study 21786177 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant 2 mg/kg IV infusion
Number of subjects: 0
Study 21786177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18609080 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg once daily
Number of subjects: 269
Study 18609080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 16869719 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/day
Number of subjects: 308
Study 16869719 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/day
Number of subjects: 308
Study 16869719 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with anastrozole and tamoxifen
Number of subjects: 308
Study 16130345 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM tutorial on HIPAA along with a journal article on HIPAA
Number of subjects: 0
Study 16130345 — intervention group
Group type: COMPARATOR
Intervention: Text-directed self-study method (control group)
Number of subjects: 0
Study 12950664 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 710
Study 12950664 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus chlorpheniramine (CQCP)
Number of subjects: 710
Study 12950664 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus ketotifen (CQK)
Number of subjects: 710
Study 12950664 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus pyrimethamine-sulphadoxine (CQPS)
Number of subjects: 710
Study 12950664 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 710
Study 12950664 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus pyrimethamine-sulphadoxine (AQPS)
Number of subjects: 710
Study 12950664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulphadoxine (PS)
Number of subjects: 710
Study 12950664 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ treatment of CQ-S infections
Number of subjects: 710
Study 12950664 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ treatment of CQ-R infections
Number of subjects: 710
Study 12950664 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ-R infections with mild resistance (RI)
Number of subjects: 710
Study 12950664 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ-R infections
Number of subjects: 710
Study 10414010 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Home Visitation Program
Number of subjects: 0
Study 7675863 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (5.0 mg/70 kg)
Number of subjects: 16
Study 7675863 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.25, 0.5, and 1.0 mg/70 kg)
Number of subjects: 16
Study 7675863 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide (30% in oxygen for 35 min)
Number of subjects: 16
Study 2142633 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil alone (1.0 micrograms.kg‐1)
Number of subjects: 30
Study 2142633 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sufentanil (0.5 micrograms.kg‐1) with lidocaine (1.5 mg.kg‐1)
Number of subjects: 30
Study 2142633 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (C)
Number of subjects: 30
Study 7383457 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone vaginal suppositories
Number of subjects: 14
Study 7383457 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 14
Study 7383457 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 14
Study 29464907 — intervention group
Group type: EXPERIMENTAL
Intervention: PAT plus a lifestyle intervention program (PAT+)
Number of subjects: 267
Study 29464907 — intervention group
Group type: COMPARATOR
Intervention: Standard PAT
Number of subjects: 267
Study 27752287 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diabetic offloading insole made from EVA/poron®
Number of subjects: 50
Study 27752287 — intervention group
Group type: EXPERIMENTAL
Intervention: Low resilient memory insole
Number of subjects: 50
Study 27752287 — intervention group
Group type: COMPARATOR
Intervention: Textured insole
Number of subjects: 50
Study 27752287 — intervention group
Group type: COMPARATOR
Intervention: Flat soft insole
Number of subjects: 50
Study 27752287 — intervention group
Group type: COMPARATOR
Intervention: No insole
Number of subjects: 50
Study 25667811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist comprehensive medication management services (PCS)
Number of subjects: 120
Study 25667811 — intervention group
Group type: COMPARATOR
Intervention: No pharmacist comprehensive medication management services (NCS)
Number of subjects: 120
Study 25667811 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 120
Study 23063027 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal/Bolus regimen with glargine/glulisine (n = 169)
Number of subjects: 472
Study 23063027 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal/Bolus regimen with detemir/aspart (n = 67)
Number of subjects: 472
Study 23063027 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal/Bolus regimen with neutral protamine Hagedorn/regular (n = 63)
Number of subjects: 472
Study 23063027 — intervention group
Group type: COMPARATOR
Intervention: Regular sliding scale insulin (SSI) (n = 173)
Number of subjects: 472
Study 23063027 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical patients
Number of subjects: 472
Study 23063027 — intervention group
Group type: COMPARATOR
Intervention: Surgical patients
Number of subjects: 472
Study 23063027 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 472
Study 23063027 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired kidney function (glomerular filtration rate < 60 ml/min)
Number of subjects: 472
Study 23063027 — intervention group
Group type: EXPERIMENTAL
Intervention: Total daily insulin dose
Number of subjects: 472
Study 23063027 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of insulin regimen (basal/bolus versus SSI)
Number of subjects: 472
Study 19544136 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily reports of vaginal sex
Number of subjects: 376
Study 19544136 — intervention group
Group type: COMPARATOR
Intervention: Retrospective reports of vaginal sex
Number of subjects: 376
Study 18762516 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antibiotic treatment (within <1 day of fever onset)
Number of subjects: 287
Study 18762516 — intervention group
Group type: COMPARATOR
Intervention: Delayed antibiotic treatment (>/=5 days after fever onset)
Number of subjects: 287
Study 17179056 — intervention group
Group type: EXPERIMENTAL
Intervention: Black cohosh, 160 mg daily
Number of subjects: 351
Study 17179056 — intervention group
Group type: EXPERIMENTAL
Intervention: Multibotanical with black cohosh, 200 mg daily, and 9 other ingredients
Number of subjects: 351
Study 17179056 — intervention group
Group type: EXPERIMENTAL
Intervention: Multibotanical plus dietary soy counseling
Number of subjects: 351
Study 17179056 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen, 0.625 mg daily, with or without medroxyprogesterone acetate, 2.5 mg daily
Number of subjects: 351
Study 17179056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 14529055 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg orally disintegrating tablet (ODT)
Number of subjects: 218
Study 11004622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 10
Study 11004622 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 10
Study 8827316 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional knee braces
Number of subjects: 5
Study 8827316 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional knee braces with lower extremity muscle activation
Number of subjects: 5
Study 1420010 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol (n = 22)
Number of subjects: 47
Study 1420010 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine (n = 25)
Number of subjects: 47
Study 6699312 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline therapy added to metaproterenol sulfate and beclomethasone dipropionate aerosol therapy
Number of subjects: 21
Study 6699312 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline therapy added to metaproterenol sulfate aerosol
Number of subjects: 21
Study 6699312 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline therapy
Number of subjects: 21
Study 31056291 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 240 mg
Number of subjects: 720
Study 31056291 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 500 mg
Number of subjects: 720
Study 29524005 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 0
Study 26760077 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedestrian safety training sessions (6 sessions of 45 crossings each) in a virtual environment
Number of subjects: 59
Study 24486635 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal educational (MME) intervention including traditional education (TE) approaches, a web-based course, and preceptor-facilitated training during a 3rd year clerkship rotation.
Number of subjects: 10
Study 24486635 — intervention group
Group type: COMPARATOR
Intervention: Traditional education (TE)
Number of subjects: 10
Study 22677092 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led self-help treatment plus usual care
Number of subjects: 268
Study 22677092 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 268
Study 19818588 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose-hip powder 5g daily
Number of subjects: 89
Study 19818588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 18311493 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 12
Study 18311493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18311493 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (on nights)
Number of subjects: 12
Study 15946834 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 microg)
Number of subjects: 26
Study 15946834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12621381 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 1000 mg every 8 hours plus rifabutin 150 mg daily
Number of subjects: 28
Study 12621381 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 150 mg daily with indinavir
Number of subjects: 28
Study 12621381 — intervention group
Group type: COMPARATOR
Intervention: Rifabutin 300 mg daily alone
Number of subjects: 28
Study 10344294 — intervention group
Group type: EXPERIMENTAL
Intervention: Test lenses with varying oxygen transmissibility
Number of subjects: 109
Study 10344294 — intervention group
Group type: EXPERIMENTAL
Intervention: Test lenses
Number of subjects: 109
Study 10344294 — intervention group
Group type: COMPARATOR
Intervention: Baseline values of outcome measures
Number of subjects: 109
Study 8559498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 5 mg/kg
Number of subjects: 7
Study 8559498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 4 mg/kg
Number of subjects: 7
Study 8559498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 3 mg/kg
Number of subjects: 7
Study 8559498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 2 mg/kg
Number of subjects: 7
Study 8559498 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 7
Study 2387651 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA 25 mg
Number of subjects: 180
Study 2387651 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA 15 mg
Number of subjects: 180
Study 2387651 — intervention group
Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 180
Study 6789951 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-gated blood-pool imaging
Number of subjects: 32
Study 6789951 — intervention group
Group type: COMPARATOR
Intervention: Contrast ventriculography
Number of subjects: 32
Study 31850778 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional toothbrush
Number of subjects: 9
Study 31850778 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone tooth and gum brush
Number of subjects: 9
Study 31850778 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents brushing with conventional toothbrush
Number of subjects: 9
Study 31850778 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents brushing with silicone tooth and gum brush
Number of subjects: 9
Study 31850778 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 9
Study 30001727 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™) administered orally at a dose of 6 mg/kg
Number of subjects: 16
Study 30001727 — intervention group
Group type: COMPARATOR
Intervention: Negative control (no treatment)
Number of subjects: 16
Study 26717057 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative immunofluorescence (QIF) model
Number of subjects: 2919
Study 26717057 — intervention group
Group type: COMPARATOR
Intervention: Conventional 3,3'-diaminobezidine (DAB) immunohistochemistry model
Number of subjects: 2919
Study 24892113 — intervention group
Group type: EXPERIMENTAL
Intervention: NobelActive implants (Nobel Biocare)
Number of subjects: 34
Study 24892113 — intervention group
Group type: COMPARATOR
Intervention: NobelSpeedy Groovy implants (Nobel Biocare)
Number of subjects: 34
Study 21512834 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-mediated communication-focused treatment for autism
Number of subjects: 28
Study 21512834 — intervention group
Group type: COMPARATOR
Intervention: Ordinary care
Number of subjects: 28
Study 20079528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg loading dose followed by 90 mg twice a day)
Number of subjects: 18624
Study 20079528 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300-600 mg loading dose or continuation with maintenance dose followed by 75 mg per day)
Number of subjects: 18624
Study 20079528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18624
Study 20079528 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18624
Study 18003434 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (different doses)
Number of subjects: 0
Study 18003434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15672272 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (2 mg estradiol valerate)
Number of subjects: 51
Study 15672272 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol plus progesterone (100 mg micronized progesterone)
Number of subjects: 51
Study 15672272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 12183095 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive palliative care program
Number of subjects: 180
Study 12183095 — intervention group
Group type: COMPARATOR
Intervention: Conventional care program (control)
Number of subjects: 180
Study 9915533 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 1 mg orally 12 hours before surgery, just before surgery, and 12 and 24 hours after surgery
Number of subjects: 156
Study 9915533 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally 12 hours before surgery, just before surgery, and 12 and 24 hours after surgery
Number of subjects: 156
Study 8740302 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (1 g/m2 per day divided into two equal doses)
Number of subjects: 69
Study 8740302 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Number of subjects: 69
Study 1655847 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 96
Study 1655847 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactional therapy
Number of subjects: 96
Study 6227304 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Hypnosis (n = 9)
Number of subjects: 17
Study 6227304 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation (n = 8)
Number of subjects: 17
Study 6227304 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 17
Study 29068267 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage (TS) palatal repair
Number of subjects: 33
Study 29068267 — intervention group
Group type: COMPARATOR
Intervention: One-stage (OS) palatal repair
Number of subjects: 33
Study 29068267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TS and OS groups
Number of subjects: 33
Study 29068267 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (not part of the trial)
Number of subjects: 33
Study 29443788 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-doses RSB analgesia
Number of subjects: 57
Study 29443788 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 26721259 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day for 21 days
Number of subjects: 25
Study 26721259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25